SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.28%14.3814.2%$232.56m
SHPGShire PLC Sponsored ADR
-1.62%145.550.4%$212.81m
PRGOPerrigo Co. Plc
-0.49%77.316.4%$151.41m
MNKMallinckrodt Plc
0.11%36.4017.7%$118.87m
UTHRUnited Therapeutics Corporation
-1.50%129.1013.9%$86.64m
JAZZJazz Pharmaceuticals Plc
-1.10%144.402.2%$77.81m
ENDPEndo International Plc
1.04%8.728.9%$71.06m
ALRAlere Inc.
0.43%49.542.7%$68.28m
HZNPHorizon Pharma plc
1.29%13.317.6%$66.17m
PRXLPAREXEL International Corporation
0.02%87.667.9%$66.07m
ICPTIntercept Pharmaceuticals, Inc.
-0.11%104.0822.1%$61.01m
NDRMNeuroDerm Ltd.
0.00%38.553.6%$48.20m
MYOKMyoKardia, Inc.
-7.18%40.383.0%$47.43m
PTLAPortola Pharmaceuticals, Inc.
1.45%53.998.9%$43.40m
MDCOMedicines Company
0.28%35.5022.3%$41.20m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.